Matches 1 - 16 out of 16


Match Document Document Title
DE102015214603A1 Phosphorus-containing aminoglycoside salts  
The object is to provide aminoglycoside compounds which ensure a sustained release of aminoglycoside over clinically relevant periods in therapeutically effective concentrations. Aminoglycoside...
DE10392697B4 Extract of peptide-linked glucans and peptide-linked Clucane with detectable oral absorbability of Coriolus Versicolor and their cleaning methods and uses  
Purified extract of Coriolus versicolor, containing at least one peptide-linked glucan, which linked by a (1 → 3) bond includes glucose molecules, an average molecular weight of 0.7 kDa to 3 kDa...
DE102004060319A1 Preparation of peptidoglycan, used e.g. to stabilize emulsions, from gram-positive bacteria comprises incubating bacteria containing biomass at defined temperature to form a mixture with e.g. solvents, soluble components and peptidoglycan  
Preparation of peptidoglycan (I) or its derivatives from gram-positive bacteria comprising isolating (I) from a biomass (A) containing the gram-positive bacteria, where the isolation is carried...
DE102004011663B4 Erythropoietin liquid formulation  
Shelf stable Erythropoietin liquid formulation, the (I) at least four amino acids selected from the group consisting from leucine, isoleucine, threonine, glutamic acid, aspartic acid and contains...
DE202004020676U1 Storage-stable liquid erythropoietin formulation, for treatment of renal insufficiency, comprises specified amino acids but no preservatives, urea or albumen and is not a reconstituted lyophilizate  
A storage-stable liquid erythropoietin (EPO) formulation (A): (i) contains at least four of the amino acids Leu, Ile, Thr, Glu, Asp or Phe; (ii) is free from preservatives, urea and human serum...
DE102004018347A1 Wundheilungsfördende messenger mixture  
The Invention relates to a wound healing-promoting neurotransmitter mixture containing platelet body fluids, the dates of in aqueous solvent insoluble Ingredients is. Furthermore, the invention...
DE102004011663A1 Erythropoietin liquid formulation  
The present invention relates to storage stable erythropoietin liquid formulations and processes for their preparation. In particular, the invention relates to Erythropoietin liquid formulations,...
DE10227914A1 Pharmaceutical formulation having retarded active substance release, methods for their preparation and use  
It pharmaceutical preparations are described having retarded active substance release, and from mixtures of powdery teicoplanin and at least one powdery, water-soluble salt form of gentamicin,...
DE10034712A1 bridged glycoconjugates  
The present invention relates to glycoconjugates, in which a protein component via a carbohydrate chain with another protein moiety, a nucleic acid or a lipid micelle or a covalently bridged. The...
DE19813137A1 New camptothecin glyco-conjugate compounds  
Camptothecin (CT) glyco-conjugates of formula (I), containing a 3-O-methylated beta -L-fucose residue bonded to the 20-hydroxy group via a thiourea-modified peptide spacer, and their salts,...
DE19719652A1 Use of tissue factor  
Use of tissue factor (I) or its fragment, to influence formation of blood vessels.
DE19710907A1 Ascorbic acid as an adjuvant in chemotherapy and radiotherapy of malignancies  
The invention relates to the use of ascorbic acid or one of its salts to produce a medicament which is suitable for parenteral application, contains more than 5 g ascorbic acid or one of its salts...
DE19512484A1 Carbohydrate-modified cytostatics  
The invention relates to cytostatics which are made tumour-specific by modification with sugar. Suitable spacers ensure serum-stability and intracellular effect at the same time.
DE4404371A1 Glycosyl of 2-aminoacylamino-2-deoxy-sugar  
The present invention relates to the nitrogen atom of the amino acid substituted (2-aminoacylamino-2-deoxy-glycosyl) -amide of the general formula (I), $ F1 wherein the substituents have the...
DE4304716A1 Local administrable sustained release drug  
A topical sustained-release pharmaceutical preparation in the form of a dry product or a suspension thereof in an inert liquid carrier containing as a sparingly water-soluble product the...
DE3909056A1 PHARMACEUTICAL KOMBINATIONSPRAEPARATE AND THEIR USE FOR THE PREVENTION OR TREATMENT OF BACTERIAL INFECTIOUS DISEASES  
Decaplanin and cephalosporin derivatives co-administer a synergistic antibacterial effect. Corresponding combination preparations are therefore suitable for the prophylaxis and treatment of...

Matches 1 - 16 out of 16